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T he steroidal mineralocorticoid receptor antagonists(MRAs) spironolactone and eplerenone have been shown
in large-scale prospective double-blind trials to reduce
cardiovascular mortality and hospitalizations for heart failure
in patients with a reduced left ventricular ejection fraction
(HFrEF).1 Their use in patients with midrange and preserved
left ventricular function (HFpEF) remains controversial.
Despite designation as a class 1 indication in current US2
and European3 guidelines for patients with HFrEF, their use
remains suboptimal in comparison to b-adrenergic blocking
agents, angiotensin-converting enzyme inhibitors, or angio-
tensin receptor blocking agents.4 The relative underuse of
MRAs in guideline-eligible patients with HFrEF5 has in large
part been attributed to the fear of inducing hyperkalemia and/
or renal insufficiency (RI), especially in patients with diabetes
mellitus (DM) and/or chronic kidney disease.6 In part these
fears have been amplified by questions raised as to their
effectiveness and safety in “real world” settings based upon
retrospective analysis of data in various registries.7,8 While
large-scale prospective randomized trials are recognized as
the criterion standard for evaluating the safety and efficacy of
new therapies for approval, the application and relevance to
clinical practice obtained from these studies to the “real
world” has been questioned because of various restrictions on
inclusion into the large-scale randomized trials and the
intensity of patient monitoring and follow-up in comparison
to clinical practice in “real world” settings. “Real world” data
regarding the safety and efficacy of a given intervention based
upon retrospective analysis of registry data have, however,
been criticized as suffering from bias by intent to treat. In an
observational study, observations are collected without
assignment, and no adjustment, however elaborate it may
be, can protect against the “unavoidable risk of selection bias
and of systematic differences in outcomes that are not due to
the treatment itself.”9 Nevertheless, registry-based analysis of
safety and efficacy of a given therapeutic intervention is
valuable in pointing out areas for further investigation.
In this issue of JAHA, Cooper et al,10 using the Get With
The Guidelines registry linked to Medicare outcome data, have
evaluated the first-time use of MRAs in high-risk patients with
either a history of DM or RI at hospital discharge after an
episode of HF. In contrast to some previous registry studies,
they included both patients with a left ventricular ejection
fraction <35% (HFrEF) as well as those with borderline
(midrange: heart failure with midrange left ventricular ejection
fraction-HFmrEF) or preserved ejection fractions (HFpEF).
They evaluated the factors favoring or not favoring the use of
a MRA at hospital discharge as well as the 30-day, 1-year, and
3-year incidence of mortality, hospitalizations for heart failure,
and hospitalization for hyperkalemia and RI. Of 16 848
eligible patients, 2067 (12.3%) were prescribed a MRA for the
first time at hospital discharge, of whom 60.5% had HFrEF. In
the overall population after inverse probability weighting, the
use of a MRA in these relatively high-risk patients with a
history of either DM and/or RI was not associated with a
significant reduction in 30-day, 1-, or 3-year mortality. MRA
use was, however, associated with a 1- and 3-year lower risk
of hospital readmissions. This benefit of MRA use was
associated with a greater risk of readmissions for hyper-
kalemia and RI at 1 and 3 years. The increased rate of
readmissions for RI was, however, restricted to those with
borderline and preserved ejection fractions.10 In the TOPCAT
(Treatment of Preserved Cardiac Function Heart Failure with
an Aldosterone Antagonist) study of patients with HFpEF
randomized to spironolactone, there was a significant
increase in the incidence of doubling of serum creatinine
but no increase in the need for renal dialysis.11 It should also
be pointed out that the absolute increase in the incidence of
hospitalizations for hyperkalemia over 3 years in the analysis
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by Cooper et al10 was relatively low and that previous studies
have suggested that the use of a MRA is associated with a
reduction in mortality in comparison to placebo in patients
with hyperkalemia, at least up to a serum K+ value of
5.5 mmol/L.12
What Are the Implications of the Findings by
Cooper et al From This “Real World” Analysis?
An analysis of “real world” data such as that by Cooper et al10
cannot provide a definitive answer as to the efficacy or safety of
MRAs in high-risk patients with HF, as pointed out above. It can,
however, suggest the need for further prospective study in
these high-risk HF patients with DM and/or RI. The evidence
available from the prospective randomized trials of MRAs in
patients with HFrEF would support the use of a MRA in these
high-risk guideline-eligible patients13 (inclusion if serum K+
<5.0 mmol/L and estimated glomerular filtration rate
>30 mL/min per 1.73 m2). Cooper et al10 also point out that
“the benefits of therapymay outweigh the risks in this high–risk
population” since there was an overall decrease in the risk of
readmissions in patients treated with a MRA. One should,
however, closely monitor these high-risk patients. Current
evidence suggests that many patients prescribed a MRA for HF
do not undergo recommended serial monitoring of serum
potassium (K+) and renal function.14 Monitoring of serum K+
and renal function would allow appropriate dose adjustment
and/or discontinuation of a MRA as well as discontinuation of
other medications that might affect renal function and thus
serum K+. Those who do undergo appropriate serial monitoring
often discontinue theirMRA because of an increase in serumK+
and/or creatinine. While clearly one would like to avoid the
increased risk of ventricular arrhythmias and sudden cardiac
death associated with the occurrence of hyperkalemia, discon-
tinuing a MRA could potentially expose the patient to an even
greater risk since the steroidal MRA eplerenone has been
shown to reduce all-cause mortality and all-cause hospitaliza-
tions in patients with HFrEF1 including those patients with DM
and/or chronic kidney disease.13 The situation in regard to the
use of aMRA in those patientswith borderline and/or preserved
ejection fractions (HFmrEF or HFpEF), especially those with DM
and/or RI, is less certain. Although spironolactone appeared to
reduce cardiovascular mortality and HFHs (Heart Failure
Hospitalizations) in the Americas region in TOPCAT, the overall
results including patients from Russia and the Republic of
Georgia, who have been found not to have had themortality rate
we expect in patients with HFpEF and in whom there is evidence
that many patients randomized to spironolactone and claiming
to have taken it did not take it,15 were not significant. Until
further strategies are identified that clearly reduce cardiovas-
cular mortality and hospitalizations for heart failure in patients
with HFmrEF and HFpEF, one should consider the use of
spironolactone in these patients as suggested by the class II
indication in current US guidelines.2 Further information in
regard to the efficacy and safety of spironolactone in patients
with midrange left ventricular function and HFpEF should be
forthcoming from the prospectively randomized open label
SPIRRIT-HFpEF (Spironolactone Initiation Registry Randomized
Interventional Trial in Heart Failure with Preserved Ejection
Fraction) (n=3200) in which the primary outcome is cardiovas-
cular mortality.16 In those patients with DM and/or RI, one
might consider it prudent to await further data from the SPIRRIT
trial16 before considering a MRA in view of the increased risk of
RI noted by Cooper et al in these patients.10 However, even in
these high-risk patients therewas a decrease in the incidence of
readmissions without any increase in mortality, which would
favor the use of a MRA. While the decision as to whether or not
to administer a MRA to these high-risk patients with borderline
and/or preserved ventricular function remains uncertain, the
data by Cooper et al10 are of value in focusing our attention on
the need to consider new strategies to reduce the risk of
hyperkalemia and RI in these high-risk patients who are at great
risk of dying of HF. The availability of new safe and well-
tolerated potassium-lowering agents such as patiromer should
avoid the risks of hyperkalemia associated with MRA use and
potentially could allow the long-term use of aMRA in these high-
risk patients despite the occurrence of hyperkalemia. The long-
term risks and benefits of such a strategy will, however, require
further prospective evaluation.17 The use of new nonsteroidal
MRAs such as Finerenone, which in early studies has been
shown to be as effective as spironolactone in reducing brain
natriuretic peptide and N-terminal pro-brain natriuretic peptide
in HF patients but associated with a lower incidence of
hyperkalemia,18 also holds promise for the high-risk patients
with HF complicated by DM and/or chronic kidney disease
identified by Cooper et al.10 Whether Finerenone improves
cardiovascular and renal outcomes in patients with diabetic
nephropathy (Figaro n=6400, clinicaltrials.gov NCT02540993),
(Fidelio n=4800, NCT02545049) is currently being evaluated.
Finally, the trend toward the design of more pragmatic
prospective randomized trials with fewer exclusions should
hopefully in the future reduce the differences between “real
world” data obtained retrospectively from registries such as
that by Cooper et al10 and the prospective randomized trials
used for drug approval. Until then, both the large-scale
prospective randomized trials and the retrospective analysis
of registries to provide “real world” data such as that by
Cooper et al10 have a role in informing clinical practice—but
in a different manner.
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